{"prompt": "['5.3.4', 'Assessment of Causality of Adverse Events', 'Investigators should use their knowledge of the patient, the circumstances surrounding the', 'event, and an evaluation of any potential alternative causes to determine whether an AE is', 'considered to be related to the study drug, indicating \"yes\" or \"no\" accordingly. The', 'following guidance should be taken into consideration (see also Table 4):', 'Temporal relationship of event onset to the initiation of study drug', 'Course of the event, with special consideration of the effects of dose reduction,', 'discontinuation of study drug, or reintroduction of study drug (as applicable)', 'Known association of the event with the study drug or with similar treatments', 'Known association of the event with the disease under study', 'Presence of risk factors in the patient or use of concomitant medications known to', 'increase the occurrence of the event', 'Presence of non-treatment-related factors that are known to be associated with the', 'occurrence of the event', 'Table 4', 'Causal Attribution Guidance', 'Is the adverse event suspected to be caused by the study drug on the basis of facts, evidence,', 'science-based rationales, and clinical judgment?', 'YES', 'There is a plausible temporal relationship between the onset of the adverse event and', 'administration of the study drug, and the adverse event cannot be readily explained by the', \"patient's clinical state, intercurrent illness, or concomitant therapies; and/or the adverse\", 'event follows a known pattern of response to the study drug; and/or the adverse event', 'abates or resolves upon discontinuation of the study drug or dose reduction and, if', 'applicable, reappears upon re challenge.', 'NO', 'An adverse event will be considered related, unless it fulfils the criteria specified below.', 'Evidence exists that the adverse event has an aetiology other than the study drug (e.g.,', 'pre-existing medical condition, underlying disease, intercurrent illness, or concomitant', 'medication); and/or the adverse event has no plausible temporal relationship to', 'administration of the study drug (e.g., cancer diagnosed 2 days after first dose of study', 'drug).', '5.3.5', 'Procedures for Recording Adverse Events', 'Investigators should use correct medical terminology / concepts when recording AEs on the', 'Adverse Event eCRF. Avoid colloquialisms and abbreviations.', 'Only one AE term should be recorded in the event field on the Adverse Event eCRF.', 'Refer to Section 5.2.4 for procedures for recording heart failure, asymptomatic decreases in', 'LVEF and ARRs.', '5.3.5.1', 'Diagnosis versus Signs and Symptoms', 'For AEs other than heart failure and ARRs (see Section 5.2.4), a diagnosis (if known) should', 'be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g.,', 'record only liver failure or hepatitis rather than jaundice, asterixis, and elevated', 'transaminases). However, if a constellation of signs and/or symptoms cannot be medically', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '71 / Protocol MO40628, Version 12']['characterized as a single diagnosis or syndrome at the time of reporting, each individual', 'event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently', 'established, all previously reported AEs based on signs and symptoms should be nullified', 'and replaced by one adverse event report based on the single diagnosis, with a starting date', 'that corresponds to the starting date of the first symptom of the eventual diagnosis.', '5.3.5.2', 'Adverse Events That Are Secondary to Other Events', 'In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae)', 'should be identified by their primary cause, with the exception of severe or serious', 'secondary events. A medically significant secondary AE that is separated in time from the', 'initiating event should be recorded as an independent event on the Adverse Event eCRF.', 'For example:', 'If vomiting results in mild dehydration with no additional treatment in a healthy adult, only', 'vomiting should be reported on the eCRF.', 'If vomiting results in severe dehydration, both events should be reported separately on', 'the eCRF.', 'If a severe gastrointestinal haemorrhage leads to renal failure, both events should be', 'reported separately on the eCRF.', 'If dizziness leads to a fall and consequent fracture, all three events should be reported', 'separately on the eCRF.', 'If neutropenia is accompanied by an infection, both events should be reported separately', 'on the eCRF.', 'All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to', 'whether the events are associated.', '5.3.5.3', 'Persistent or Recurrent Adverse Events', 'A persistent AE is one that extends continuously, without resolution, between patient', 'evaluation timepoints. Such events should only be recorded once on the Adverse Event', 'eCRF. The initial severity (intensity or grade) of the event will be recorded at the time the', 'event is first reported. If a persistent AE becomes more severe, the most extreme severity', 'should also be recorded on the Adverse Event eCRF. If the event becomes serious, it should', 'be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the', 'event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event', 'eCRF should be updated by changing the event from \"non-serious\" to \"serious,\" providing', 'the date that the event became serious, and completing all data fields related to SAEs.', 'A recurrent AE is one that resolves between patient evaluation timepoints and subsequently', 'recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse', 'Event eCRF.', '5.3.5.4', 'Abnormal Laboratory Values', 'Not every laboratory abnormality qualifies as an AE. A laboratory test result must be', 'reported as an AE if it meets any of the following criteria:', 'Is accompanied by clinical symptoms', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '72 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}